logo

For the Inventor, By the Inventor

East Brunswick, NJ, United States of America

Raymond Yu

USPTO Granted Patents = 11 

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 72(Granted Patents)


Company Filing History:

goldMedal11 out of 75 
 
Medical Diagnostic Laboratories, LLC
 patents

Years Active: 2012-2022

Loading Chart...
11 patents (USPTO):Explore Patents
1. RE49026 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2022-04-11),
2. 10416172 - Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling (2019-09-17),
3. 9868776 - Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2018-01-16),
4. 9605027 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2017-03-28),
5. 9523073 - Elisa for a naturally-occurring soluble truncated form of IL-23 receptor (2016-12-20),
6. 9187750 - Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2015-11-17),
7. 9169292 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2015-10-27),
8. 8946150 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2015-02-03),
9. 8618070 - Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2013-12-31),
10. 8404824 - Splice variants of human IL-23 receptor (IL-23R) mRNA and use of a Δ9 isoform in predicting inflammatory bowel diseases (2013-03-26),
11. 8206925 - Splice variants of human IL-23 receptor (IL-23R) mRNA and use of a delta 9 isoform in predicting inflammatory bowel diseases (2012-06-26),

Title: Innovations by Inventor Raymond Yu

Introduction

Raymond Yu is a prominent inventor based in East Brunswick, NJ (US), known for his significant contributions to the field of medical diagnostics and therapeutic innovations. With a total of 11 patents to his name, he has made remarkable strides in developing solutions for various human diseases.

Latest Patents

One of his latest patents involves the creation of polypeptides that bind to the IL-23 receptor, inhibiting the binding of IL-23 and its associated cell signaling. This invention focuses on novel linear and cyclic polypeptides with a core structure of WXXXW, where W represents tryptophan, and X represents other amino acids. These polypeptides have potential applications in treating IL-23 associated diseases such as inflammatory bowel diseases, psoriasis, and multiple sclerosis.

Another significant patent by Raymond Yu is the recombinant soluble truncated IL-23 receptor (IL-23R), which is capable of inhibiting IL-23R-mediated cell signaling. This isolated protein, resulting from a splice variant of IL-23R, serves as a diagnostic tool for autoimmune diseases, including Crohn's disease. The therapeutic applications of this protein are promising, particularly in treating patients afflicted with Crohn's disease.

Career Highlights

Raymond Yu currently works at Medical Diagnostic Laboratories, LLC, where he continues to innovate and contribute to the field of medical diagnostics. His work has been instrumental in advancing the understanding and treatment of various autoimmune diseases.

Collaborations

Raymond collaborates with notable colleagues, including Grant E Gallagher and Jonathan Brazaitis, who contribute to his research and development efforts.

Conclusion

Raymond Yu's innovative work in developing polypeptides and soluble receptors has the potential to significantly impact the treatment of autoimmune diseases. His contributions to medical diagnostics and therapeutics highlight the importance of innovation in improving human health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…